Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics Plc ADR (NQ: AUTL )

4.175 -0.015 (-0.36%)
Streaming Delayed Price Updated: 10:02 AM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Autolus Therapeutics Plc ADR

< Previous 1 2 3 Next >
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics PLC (NASDAQ: AUTL) Climbs to New 52-Week High
Via Investor Brand Network
Autolus Therapeutics Announces Changes to its Board of Directors
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces publication in Blood Cancer Journal
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces publication in Nature Communications
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Announces Pricing of Underwritten Offering
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces publication in ACS Chemical Biology
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Announces Changes to its Board of Directors
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces participation in upcoming conferences
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
From Autolus Therapeutics plc
Via GlobeNewswire
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces publication in Cancer Immunology Research
From Autolus Therapeutics plc
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.